Advertisement
Advertisement
Viking Therapeutics, Inc. (VKTX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
As of 12:32PM EST. Market open.
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 5.1900 |
| Open | 5.2000 |
| Bid | 4.9700 x 900 |
| Ask | 4.9800 x 1000 |
| Day's Range | 4.9500 - 5.2000 |
| 52 Week Range | 4.9150 - 10.0900 |
| Volume | |
| Avg. Volume | 600,362 |
| Market Cap | 386.596M |
| Beta (5Y Monthly) | 1.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5990 |
| Earnings Date | Feb 15, 2022 - Feb 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.10 |
- Zacks
Novartis (NVS) Highlights Growth Profile at its R&D Day
Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.
- Zacks
Fennec (FENC) Gets CRL From FDA for Pedmark, Stock Down
Fennec (FENC) suffers a setback again with a CRL for its new drug application (NDA) for Pedmark. Shares are down in pre-market trading.
- Zacks
Bristol Myers' (BMY) Cardiovascular Drug Review Extended by FDA
Bristol Myers (BMY) announces extension of FDA review of its cardiovascular drug mavacamten. The new target action date is Apr 28, 2022.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2021 Yahoo. All rights reserved.
